<DOC>
	<DOCNO>NCT01561417</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial demonstrate bio-equivalence market activated recombinant human factor VII ( NovoSeven® ) ( CP-rFVIIa ) new formulation stable 25°C ( VII25 ) .</brief_summary>
	<brief_title>Bioequivalence NovoSeven® NovoSeven® Formulation Stable Room Temperature Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Hemorrhagic Disorders</mesh_term>
	<mesh_term>Thrombasthenia</mesh_term>
	<criteria>Caucasian Body Mass Index ( BMI ) 18 27 kg/m^2 , inclusive Good health indicate medical history , physical examination include vital sign ECG , clinical laboratory test result Smoke le 10 cigarette ( equivalent ) per day Capable give write Informed Consent ( IC ) Evidence clinically relevant pathology potential thromboembolic risk base medical and/or family history judge Investigator Known history atherosclerosis , arteriosclerosis , thromboembolic event know high level Troponin I Known suspect allergy activate recombinant human factor VII related product component formulation Overt bleeding , include gastrointestinal tract Hepatitis ( B C ) infection HIV ( human immunodeficiency virus ) infection</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>